Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Roche Notches Big IO Win With Tecentriq/Avastin Combo In First-Line HCC

Oct 21 2019

• By Joseph Haas

Roche hopes to offer the first OS improvement in more than a decade in HCC

Related Content

First In 10 Years, But Lenvima's First-Line Liver Label Could Be Challenged Soon

Aug 17 2018

BMS' Bid For Opdivo In First-Line HCC Stymied

Jun 24 2019

Narrow HCC CheckMate-459 Miss For Opdivo Points The Way For Combos, Roche Shows How

Sep 27 2019

Merck's Keytruda Loss In Liver Cancer Could Be Gain For Rivals

Feb 20 2019

Related Companies

Roche Holding AG

Merck & Co., Inc.

Bristol Myers Squibb Company

Genentech, Inc.

Bayer AG

Amgen, Inc.

Eisai Co., Ltd.

AstraZeneca PLC

Additional Topics

Clinical Trials ImmunoOncology Business Strategies Commercial Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window